Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Emer Leahy"'
Autor:
Alberto Ambesi-Impiombato, Kimberly Cox, Sylvie Ramboz, Daniela Brunner, Mukesh Bansal, Emer Leahy
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Drug-induced Behavioral Signature Analysis (DBSA), is a machine learning (ML) method for in silico screening of compounds, inspired by analytical methods quantifying gene enrichment in genomic analyses. When applied to behavioral data it can identify
Externí odkaz:
https://doaj.org/article/78fbc2a580bc4b54a731f043a3268675
Autor:
Jesse E Hanson, Hank La, Emile Plise, Yung-Hsiang Chen, Xiao Ding, Taleen Hanania, Emily V Sabath, Vadim Alexandrov, Dani Brunner, Emer Leahy, Pascal Steiner, Lichuan Liu, Kimberly Scearce-Levie, Qiang Zhou
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e69964 (2013)
Suberoylanilide hydroxamic acid (SAHA) is an inhibitor of histone deacetylases (HDACs) used for the treatment of cutaneous T cell lymphoma (CTCL) and under consideration for other indications. In vivo studies suggest reducing HDAC function can enhanc
Externí odkaz:
https://doaj.org/article/addf2a25361642e3b585a1287e45a910
Autor:
Una Campbell, Kerry L. Spear, Taleen Hanania, Seth C. Hopkins, Liming Shao, John Emmerson Campbell, Emer Leahy, Philip Jones, Nina Dedic, Kenneth S. Koblan, Thomas H. Large, Robert Lew
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 371:1-14
For the past 50 years, the clinical efficacy of antipsychotic medications has relied on blockade of dopamine D2 receptors. Drug development of non-D2 compounds, seeking to avoid the limiting side effects of dopamine receptor blockade, has failed to d
Autor:
Merel Ritskes-Hoitinga, Ulrich Dirnagl, Malcolm Macleod, Thomas Steckler, Jan Vollert, Esther Schenker, Anton Bespalov, Hanno Wuerbel, Heidrun Potschka, Kimberley E Wever, Bruce Altevogt, Andrew S C Rice, Judi Clark, Emily Sena, Bruno Boulanger, Gernot Riedel, Bettina Platt, Annesha Sil, Martien J Kas, Bernhard Voelkl, Mathias Jucker, Bettina M Wegenast-braun, René Bernard, Esmeralda Heiden, Ann-marie Waldron, Maarten Loos, Pim Drinkenburg, Juan Diego Pita almenar, David Gallacher, Anja Gilis, Greet Teuns, Karsten Wicke, Sabine Grote, Bernd Sommer, Janet Nicholson, Sanna Janhunen, Sami Virtanen, Kristin Cheng, Sylvie Ramboz, Emer Leahy, Isabel A Lefevre, Fiona Ducrey, Javier Guillen, Patri Vergara, Kimberley Wever, Martin Michel, Tom van de Casteele, Martin C Michel, Tom Van De Casteele, Henk Van Der Linde, Isabel Seiffert
Publikováno v:
BMJ Open Science, Vol 4, Iss 1 (2020)
Over the last two decades, awareness of the negative repercussions of flaws in the planning, conduct and reporting of preclinical research involving experimental animals has been growing. Several initiatives have set out to increase transparency and
Computational Analysis of Multidimensional Behavioral Alterations After Chronic Social Defeat Stress
Autor:
Irene Morganstern, Zachary S. Lorsch, Alberto Ambesi-Impiombato, Emer Leahy, Taleen Hanania, Rebecca Zenowich, Mukesh Bansal, Eric J. Nestler
Publikováno v:
Biological psychiatry. 89(9)
Background The study of depression in humans depends on animal models that attempt to mimic specific features of the human syndrome. Most studies focus on one or a few behavioral domains, with time and practical considerations prohibiting a comprehen
Autor:
Nina, Dedic, Philip G, Jones, Seth C, Hopkins, Robert, Lew, Liming, Shao, John E, Campbell, Kerry L, Spear, Thomas H, Large, Una C, Campbell, Taleen, Hanania, Emer, Leahy, Kenneth S, Koblan
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 371(1)
For the past 50 years, the clinical efficacy of antipsychotic medications has relied on blockade of dopamine D
Autor:
Shereen Ezzat, Anil K. Rustgi, Stuart L. Schreiber, Kay Washington, Arul M. Chinnaiyan, Andrew L. Kung, Elena V. Komissarova, Charles Karan, Beatrice S. Knudsen, Diane Reidy-Lagunes, Daniel Diolaiti, Zhong Li, Irvin M. Modlin, Roberto Bergamaschi, Andrea Frilling, Jakob Regberg, David C. Metz, Filemon S. Dela Cruz, Deepti Dhall, Douglas A. Fraker, Emer Leahy, Ülo Langel, Ronald Realubit, Laura H. Tang, Stefano Serra, Afshin Ghavami, Prem S. Subramaniam, Antonia R. Sepulveda, Tony Detre, Lisa Bodei, Jeffrey W. Milsom, Xiaopu Yuan, Mark Kidd, Andrea Califano, Daniel Kaemmerer, Kyoung Mi Kim, Young Suk Park, Mariano J. Alvarez, Paul A. Clemons, Elizabeth A. Hagan, Robert E. Roses, Helen Remotti, Jeeyun Lee, Hai Li, Roswitha Pfragner, Massimo Barberis, Merten Hommann, Virginia A. LiVolsi, Allison R. Rainey, Michelle K. Kim, Adina Grunn, Gabrielle E. Rieckhof, Chanjuan Shi, Bertram Wiedenmann, Hee C. Kim, Dirk Jaeger, Lakshmi P. Kunju, Mahalaxmi Aburi
Publikováno v:
Nat Genet
We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their ability to invert the concerted a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4d09dc99068d6a36407f03e9aa66176
http://hdl.handle.net/10044/1/60492
http://hdl.handle.net/10044/1/60492
Autor:
Thomas Steckler, Jan Vollert, Esther Schenker, Anton Bespalov, Hanno Wuerbel, Martin Christian Michel, Heidrun Potschka, Kimberley E Wever, Bruce Altevogt, Andrew S C Rice, Judi Clark, Bruno Boulanger, Gernot Riedel, Bettina Platt, Annesha Sil, Martien J Kas, Bernhard Voelkl, Mathias Jucker, Bettina M Wegenast-braun, René Bernard, Esmeralda Heiden, Ann-marie Waldron, Maarten Loos, Tom Van De casteele, Pim Drinkenburg, Juan Diego Pita almenar, David Gallacher, Henk Van Der linde, Anja Gilis, Greet Teuns, Karsten Wicke, Sabine Grote, Bernd Sommer, Janet Nicholson, Sanna Janhunen, Sami Virtanen, Kristin Cheng, Sylvie Ramboz, Emer Leahy, Isabel A Lefevre, Fiona Ducrey, Javier Guillen, Patri Vergara, Thomas Ingraham
Publikováno v:
BMJ Open Science
BMJ Open Science, Vol 2, Iss 1 (2018)
Vollert, J, Schenker, E, Macleod, M, Bespalov, A, Wuerbel, H, Michel, M C, Dirnagl, U, Potschka, H, Wever, K E, Steckler, T, Altevogt, B & Rice, A S C 2018, ' Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals ', BMJ Open Science, vol. 2, no. 1, pp. e000004 . https://doi.org/10.1136/bmjos-2018-000004
Vollert, Jan; Schenker, Esther; Macleod, Malcolm; Bespalov, Anton; Würbel, Hanno; Michel, Martin Christian; Dirnagl, Ulrich; Potschka, Heidrun; Wever, Kimberley E; Steckler, Thomas; Altevogt, Bruce; Rice, Andrew S C (2018). Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals. BMJ open science, 2(1), e000004. BMJ Publishing Group 10.1136/bmjos-2018-000004
BMJ Open Science, Vol 2, Iss 1 (2018)
Vollert, J, Schenker, E, Macleod, M, Bespalov, A, Wuerbel, H, Michel, M C, Dirnagl, U, Potschka, H, Wever, K E, Steckler, T, Altevogt, B & Rice, A S C 2018, ' Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals ', BMJ Open Science, vol. 2, no. 1, pp. e000004 . https://doi.org/10.1136/bmjos-2018-000004
Vollert, Jan; Schenker, Esther; Macleod, Malcolm; Bespalov, Anton; Würbel, Hanno; Michel, Martin Christian; Dirnagl, Ulrich; Potschka, Heidrun; Wever, Kimberley E; Steckler, Thomas; Altevogt, Bruce; Rice, Andrew S C (2018). Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals. BMJ open science, 2(1), e000004. BMJ Publishing Group 10.1136/bmjos-2018-000004
Objective Within the last years, there has been growing awareness of the negative repercussions of unstandardized planning, conduct and reporting of preclinical and biomedical research. Several initiatives have set the aim of increasing validity and
Publikováno v:
European journal of pharmacology
Drug testing with traditional behavioral assays constitutes a major bottleneck in the development of novel therapies. PsychoGenics developed three comprehensive highthroughtput systems, SmartCube®, NeuroCube® and PhenoCube® systems, to increase th
Publikováno v:
European Journal of Pharmacology. 750:82-89
Drug testing with traditional behavioral assays constitutes a major bottleneck in the development of novel therapies. PsychoGenics developed three comprehensive high-throughput systems, SmartCube(®), NeuroCube(®) and PhenoCube(®) systems, to incre